Subscribe to WHX Insights newsletter
Stay at the forefront of healthcare trends & innovations
Upgrade your blood cancer diagnostics now
January 5, 2025
1 Min Read
Traditional methods miss critical genetic signals that determine patient outcomes. Molecular testing detects disease at previously impossible levels — delivering earlier intervention, personalised treatment, and dramatically improved survival. Here's how to implement precision diagnostics today.
Deploy molecular assays that change outcomes
Implement testing that identifies:
BCR-ABL1 fusion (CML/ALL)—predict treatment response and adjust therapy in real-time
PML-RARA translocation (APL)—enable targeted therapy that transforms survival rates
JAK2 V617F mutation—guide myeloproliferative neoplasm treatment
Action: Audit current protocols and identify where molecular assays fill diagnostic gaps.
Adopt precision technologies
PCR/qPCR: Detect mutations and monitor disease burden in CML
NGS panels: Analyse multiple genes simultaneously to uncover novel mutations
Digital PCR: Achieve MRD detection for early relapse prediction
Action: Prioritise one technology upgrade this quarter based on your highest-volume malignancies.
Monitor continuously
Track deep molecular response in CML—correlates with long-term remission
Use MRD assessment in ALL to drive therapy intensification or transplant decisions
Establish regular molecular surveillance protocols
Action: Create standardised monitoring schedules for your top three malignancies within 60 days.
Standardise to scale
Adopt international guidelines (e.g., European LeukemiaNet)
Implement quality assurance across molecular testing workflows
Participate in external quality assessment programmes
Action: Conduct inter-lab comparison to identify and eliminate variability.
Integrate AI to accelerate decisions
Deploy AI platforms for variant interpretation and risk stratification
Automate workflows to reduce turnaround times
Leverage cloud solutions for real-time global collaboration
Action: Pilot one AI analytics tool within six months—measure impact on reporting speed and accuracy.
The call to action
Molecular diagnostics are the standard of care. Labs and clinicians who implement these technologies now will deliver measurably better outcomes.
Your move: Execute one action step this quarter. Patient survival depends on it.
Joowon Oh is the Consultant Physician and Lead of Genetics and Cytogenetics at PureLab. Read her full story on WHX Insights newspaper
WHX Labs Dubai
Jan 26, 2027 TO Jan 29, 2027
|Dubai, UAE
Join us at WHX Labs Dubai—the world's #1 medical lab event. WHX Labs Dubai, formerly Medlab Middle East, is built on a legacy of 25 years of laboratory innovation and uniting communities for better health. It brings the medical lab community from all over the world together under one roof. From the latest technology to the brightest minds, it's the go-to place where you can accelerate your lab.
